Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel B Jones

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Kidney International|March 20, 2023
Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitisNicolas Benichou, Pierre Charles, Benjamin Terrier, et al.
Kidney International Reports|April 20, 2026
Systematic Review of Trial Design and End Points in Lupus NephritisSophia Giang, Maria A Dall'Era, Rachel B Jones, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 28, 2019
Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathyChristine Barrett, Lisa C Willcocks, Rachel B Jones, et al.
Arthritis and Rheumatism|July 1, 2009
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitisRachel B Jones, Alastair J Ferraro, Afzal N Chaudhry, et al.
Rheumatology (Oxford, England)|November 3, 2020
Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction modelsMark E McClure, Yajing Zhu, Rona M Smith, et al.
BMC Musculoskeletal Disorders|June 3, 2014
The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune diseaseHelena Marco, Rona M Smith, Rachel B Jones, et al.
Rheumatology Advances in Practice|August 21, 2024
Long-term surveillance study of rituximab originator treated patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)Lisa Uchida, Rachel B Jones, Rona M Smith, et al.
Journal of the American Society of Nephrology : JASN|November 19, 2011
Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapyAnnelies E Berden, Rachel B Jones, Dianhdra D Erasmus, et al.
BMJ Open|July 17, 2024
Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVasDominic Paul McGovern, Mark E McClure, Matthew Coates, et al.
Kidney Medicine|August 12, 2024
Glucocorticoid Minimization in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An International Survey of CliniciansDavid Massicotte-Azarniouch, Mark Canney, Priscilla Karnabi, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Kidney International|March 20, 2023
Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitisNicolas Benichou, Pierre Charles, Benjamin Terrier, et al.
Kidney International Reports|April 20, 2026
Systematic Review of Trial Design and End Points in Lupus NephritisSophia Giang, Maria A Dall'Era, Rachel B Jones, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 28, 2019
Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathyChristine Barrett, Lisa C Willcocks, Rachel B Jones, et al.
Arthritis and Rheumatism|July 1, 2009
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitisRachel B Jones, Alastair J Ferraro, Afzal N Chaudhry, et al.
Rheumatology (Oxford, England)|November 3, 2020
Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction modelsMark E McClure, Yajing Zhu, Rona M Smith, et al.
BMC Musculoskeletal Disorders|June 3, 2014
The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune diseaseHelena Marco, Rona M Smith, Rachel B Jones, et al.
Rheumatology Advances in Practice|August 21, 2024
Long-term surveillance study of rituximab originator treated patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)Lisa Uchida, Rachel B Jones, Rona M Smith, et al.
Journal of the American Society of Nephrology : JASN|November 19, 2011
Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapyAnnelies E Berden, Rachel B Jones, Dianhdra D Erasmus, et al.
BMJ Open|July 17, 2024
Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVasDominic Paul McGovern, Mark E McClure, Matthew Coates, et al.
Kidney Medicine|August 12, 2024
Glucocorticoid Minimization in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An International Survey of CliniciansDavid Massicotte-Azarniouch, Mark Canney, Priscilla Karnabi, et al.
Pageof 6